BofA Merrill Lynch and Cowen are joint bookrunning managers for deal
By Devika Patel
Knoxville, Tenn., Feb. 5 – Nexvet Biopharma plc said it priced its $40 million initial public sale of stock with a $6 million greenshoe. The deal was announced Jan. 26.
The company will sell 4 million ordinary shares at $10.00 per share.
BofA Merrill Lynch and Cowen and Co. are the bookrunning managers.
Proceeds will be used for research, studies, regulatory compliance and to complete the development and manufacturing scale-up of products.
The clinical-stage biopharmaceutical company is based in Dublin. The company intends to list its stock on the Nasdaq stock exchange under the symbol “NVET.”
| Issuer: | Nexvet Biopharma plc
|
| Issue: | Ordinary stock
|
| Amount: | $40 million
|
| Greenshoe: | $6 million
|
| Shares: | 4 million
|
| Price: | $10.00
|
| Warrants: | No
|
| Bookrunners: | BofA Merrill Lynch and Cowen and Co.
|
| Co-managers: | Piper Jaffray and JMP Securities
|
| Announcement date: | Jan. 26
|
| Pricing date: | Feb. 5
|
| Stock exchange: | Nasdaq: NVET
|
|
|
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.
